Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

aTYR PHARMA INC Director's Dealing 2021

May 20, 2021

34337_dirs_2021-05-20_883e5acc-7744-4ec2-92ea-e63ca1b0b6d7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2021-05-18

Reporting Person: SCHIMMEL PAUL (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-05-18 Common Stock P 50000 $3.98 Acquired 113023 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 2890 Direct
Common Stock 429143 Indirect

Footnotes

F1: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.

F2: Represents weighted average price for the shares. The shares were purchased at prices ranging from $3.95 to $4.00 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.

F3: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel.